Samsung Bioepis to Initiate Phase 1 Clinical Trial of SB26 Ulinastatin-Fc...
INCHEON, Korea Samsung Bioepis Co., Ltd. today announced it will soon begin a Phase 1 study to evaluate SB26 in healthy volunteers. SB26, also known as TAK-671, is a ulinastatin-Fc (UTI-Fc) fusion...
View ArticleNew Study Investigates the Utility of Home Monitoring Using Masimo SET® Pulse...
SOUTHAMPTON, England Masimo (NASDAQ: MASI) announced today the findings of a recently published study in which researchers investigated whether home pulse oximetry monitoring might be a useful...
View Articleダウン症候群の小児を対象とする睡眠時障害診断のマルチチャンネル研究に先立つ閉塞性睡眠時無呼吸症リスクのスクリーニングとしてMasimo...
英サウサンプトン (ビジネスワイヤ)– マシモ(NASDAQ:...
View Article新研究调查诊断性多通道睡眠检查之前采用Masimo SET®脉搏氧饱和度仪居家监测筛查唐氏综合征患儿罹患阻塞性睡眠呼吸暂停的风险
英格兰南安普顿 (美国商业资讯) — Masimo (NASDAQ: MASI)今天发布了最近发表的一项研究结果,该研究中,研究人员调查居家脉搏氧饱和度仪监测能否作为有用的初步筛查方法,用于确定推荐哪些唐氏综合征(DS)患儿通过多通道睡眠检查来诊断该病,DS患儿是阻塞性睡眠呼吸暂停(OSA)的高危人群。居家监测采用的是Masimo SET®移动和低灌注下测量(Measure-through...
View ArticleAVEO Announces Acceptance of CANbridge Investigational New Drug Application...
CAMBRIDGE, Mass. AVEO Oncology (Nasdaq: AVEO) today announced that the China National Drug Administration (CNDA) has accepted CANbridge Life Sciences’ Investigational New Drug (IND) Application for...
View ArticleCANbridge Life Sciences Receives Approval to Commence CAN017 Ib/III Trial in...
BEIJING CANbridge Life Sciences, a biopharmaceutical company developing Western drug candidates in China and North Asia, announced that the China National Drug Administration (CNDA) has approved the...
View ArticleHarbour BioMed Announces Global Strategic Partnership with Kelun-Biotech to...
SHANGHAI & CHENGDU, China & BOSTON & CRANBURY, N.J. Harbour BioMed today announced it has entered into an exclusive strategic partnership with Sichuan Kelun-Biotech Biopharmaceutical...
View ArticleEvaluate Ltd: Small Drug Developers Continue to Hold All the Cards, While...
LONDON & BOSTON & TOKYO The first half of 2018 has seen biopharma IPOs and venture financing accelerate from the already-healthy levels witnessed in 2017. Deal making has dimmed further,...
View ArticleAVITA Medical Announces Presentation of RECELL® Device Effectiveness and...
VALENCIA, Calif. & MELBOURNE, Australia AVITA Medical (ASX: AVH, OTCQX: AVMXY) today announced that results from two U.S. pivotal clinical trials demonstrating the effectiveness and clinical...
View Article美国政府向22nd Century订购360万支SPECTRUM®研究用香烟
纽约州克拉伦斯 (美国商业资讯) — 22nd Century Group, Inc. (NYSE American: XXII)是一家专注于烟草减害和极低尼古丁烟草的植物技术公司,公司今天宣布,国立药品滥用研究院(NIDA)、美国食品药品管理局(FDA)以及公共卫生研究人员新近求购大量22nd Century的专利SPECTRUM®研究用香烟。经与NIDA、FDA及各方协调,RTI...
View ArticleGlobal Virus Network Adds Singapore Consortium as Newest Center of Excellence
BALTIMORE & SINGAPORE The Global Virus Network (GVN) and the GVN-Singapore Center of Excellence, comprised of 7 virology research intuitions led by Duke-NUS Medical School, announced today the...
View ArticlePfizer and Astellas Amend Clinical Research Protocols for Two Phase 3 Trials...
NEW YORK & TOKYO Pfizer Inc. (NYSE:PFE) and Astellas Pharma Inc. (TSE:4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) today announced amendments to the protocols for two...
View ArticleAVITA Medical Announces Commencement of Manufacturing of RECELL® Device in...
VALENCIA, Calif. & MELBOURNE, Australia AVITA Medical (ASX: AVH, OTCQX: AVMXY) today announced the successful completion of multiple production runs for the RECELL Device® within its newly...
View Article22ndセンチュリー、米国政府研究用のスペクトラム紙巻きたばこ360万本を受注
米ニューヨーク州クラレンス (ビジネスワイヤ) — タバコの有害性低減と超低ニコチンタバコに傾注する植物バイオテクノロジー企業の22ndセンチュリー・グループ(NYSE American:...
View Article和铂医药完成B轮融资8500万美元 加速创新产品线研发
中国上海、荷兰鹿特丹、美国马萨诸塞州剑桥 和铂医药今天宣布成功完成B轮融资8500万美元,以加速公司创新产品线的成长,尤其是公司临床阶段项目及临床前项目的快速推进。本轮融资由新加坡政府投资公司GIC领投,国寿大健康基金、祥峰投资参与,A轮投资机构尚珹资本与君联资本跟投。...
View ArticleHarbour BioMed Raises $85 Million in Series B Financing to Accelerate Its...
SHANGHAI & ROTTERDAM, The Netherlands & CAMBRIDGE, Mass. Harbour BioMed announced today that it has completed a Series B round financing of $85 million to accelerate the growth of its...
View ArticleNew Study Evaluates the Ability of Masimo ORi™ to Reflect Oxygenation During...
NEUCHATEL, Switzerland Masimo (NASDAQ: MASI) announced today the findings of a study recently published in Anesthesia & Analgesia in which researchers at the University of Groningen, the...
View Article新近研究评估Masimo ORi™反映中度高氧期间氧合状况的功能
瑞士纳沙泰尔 (美国商业资讯) — Masimo (NASDAQ: MASI)今天发布了《麻醉与镇痛》杂志最近发表的一项研究成果,该研究中,荷兰格罗宁根大学与比利时根特大学的研究人员调查了 Masimo...
View Article